MARKET OVERVIEW
The global pharmacovigilance and drug safety software market reached USD 214.2 Million in 2024 and is expected to expand to USD 350.8 Million by 2033, growing at a CAGR of 5.63%. Growth is supported by the rising prevalence of chronic illnesses, increasing regulatory complexities, and advancements in integrated, user-friendly software platforms. These factors are positioning the market for steady expansion in the coming years.
STUDY ASSUMPTION YEARS
Base Year: 2024
Historical Years: 2019–2024
Forecast Years: 2025–2033
PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET KEY TAKEAWAYS
- Global market size was USD 214.2 Million in 2024 and is projected to hit USD 350.8 Million by 2033, reflecting a CAGR of 5.63%.
- North America (United States, Canada) is the leading regional market.
- By Functionality, Adverse Event Reporting Software dominates.
- In Delivery Mode, On-premises solutions hold the largest share.
- Among End Users, Contract Research Organizations (CROs) are the top adopters.
- Market growth is fueled by chronic disease prevalence, regulatory enforcement, and advancements in usability and integration of pharmacovigilance platforms.
Request for a sample copy of this report: https://www.imarcgroup.com/pharmacovigilance-drug-safety-software-market/requestsample
MARKET GROWTH FACTORS
- Pharmaceutical Industry Expansion
The rapid expansion of the pharmaceutical sector, highlighted by the growing launch of new drugs and therapies, is a key driver of the pharmacovigilance and drug safety software market. Increasing drug portfolios generate vast amounts of safety data, requiring advanced software solutions for real-time monitoring, in-depth analysis, and compliance reporting. AI and machine learning tools are increasingly applied to manage large-scale adverse event datasets, helping stakeholders proactively detect risks and ensure safety. - Rising Incidence of Adverse Drug Reactions (ADRs)
The global rise in adverse drug reactions has intensified the need for effective safety monitoring systems. With more ADR cases being reported and regulators imposing stricter requirements, organizations are embracing robust pharmacovigilance platforms. These solutions help process high volumes of data, identify patterns, and ensure compliance while minimizing risks—directly driving software adoption. - Increased Healthcare Expenditure and Technological Advancements
Global healthcare spending is driving investments in patient safety and digital health infrastructure. Pharmacovigilance and drug safety software plays a crucial role by enhancing ADR reporting, analytics, and risk management. Meanwhile, technology advancements such as user-friendly designs, seamless integration, and scalability are accelerating adoption across research organizations and healthcare providers. These innovations are opening new opportunities for growth in the market.
MARKET SEGMENTATION
Breakup by Functionality:
- Adverse Event Reporting Software
- Drug Safety Audits Software
- Issue Tracking Software
- Fully Integrated Software
Breakup by Delivery Mode:
- On-premises
- Cloud-based
Breakup by End User:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Business Process Outsourcing Firms
- Others
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
REGIONAL INSIGHTS
North America dominates the global pharmacovigilance and drug safety software market, supported by a strong pharmaceutical base, cutting-edge IT infrastructure, and collaborative initiatives across healthcare, academia, and technology. Strict regulatory frameworks in the region further promote faster adoption of advanced pharmacovigilance solutions.
RECENT DEVELOPMENTS & NEWS
- In February 2023, ArisGlobal launched a regulatory information management solution designed for investigational-stage firms to accelerate clinical progress.
- In June 2022, Tata Consultancy Services rolled out the TCS Servitization Engine on Oracle Cloud, offering subscription-first intelligent service models.
- In October 2022, Cognizant partnered with Qualcomm to establish a 5G experience center, enabling next-generation digital transformation in life sciences.
These initiatives underscore the industry’s emphasis on regulatory-driven, scalable, and technology-forward pharmacovigilance platforms.
KEY PLAYERS
- Ab Cube
- Anju Software Inc.
- ArisGlobal LLC
- Cognizant
- Ennov Solutions Inc.
- Extedo GmbH
- Max Application
- Oracle Corporation
- Sarjen Systems Pvt Ltd
- Sparta Systems Inc. (Honeywell International Inc.)
- Tata Consultancy Services Limited
- United BioSource LLC
- Wipro Limited
If you require any specific information not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5030&flag=C
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel (India): +91 120 433 0800 | United States: +1-201-971-6302
